God is our Guide                 Number 1 site for helping reverse diseases on Planet Earth
cidpUSA Foundation

 cidpusa.org   

      

 
      Home
      Diagnosis
      Treatment
      Pathology
      Variants
      CIDP info
      Fibromyalgia
      IVIG
      Diet anti-inflammatory
      Burning  Feet Home
      Services Page
      Chronic Fatigue
      Autoimmune diseases
      Prognosis
      Bible healing
      Celiac disease
Autoimmune self attack

Cancer therapy

Cancer cure

Vitamins and cancer

Cancer Prevention

B-17 cancer

Cancer and Bacteria

Noise in artery

Urine

Buddhism

Sjogrens

Cholesterol drugs & Bleedin

Toxic Baby products

Infants  and women omega-3

 Selenium

Basil

Bay leaves

Eliminate insulin implants

Sugar treatment

Heart FAILURE

Irregular periods

Myasthenia diet

Prophets

cancer survivor

Tomato as a medicine

New Vaccine
  Natural Makeup
  Neck Pain
  Ocular Female diseases
  Chronic fatigue syndrome
  Osteoporosis
  Women Heart Attacks
  Breast Size & Disease
  Female Sex Disease
  PARKINSON
  Memory problems
  Breast Lymph Drainage
  Kidney stone Buster
 Bras cause breast cancer
  Skin repair Clinic
 Pandas
  Hepatitis

Risk of heart disease & stroke 

Depression and breast cancer

Kidney stone removal 

Alopecia general

Personality

Skin hair nail spa

Memory clinic

Depression & anxiety

Addiction  & Drug Rehab

Sexual  disorders Clinic

Parkinson Clinic

Epilepsy Clinic

Pain Clinic

Bone disorders clinic

Joint disorder clinic

Neurology Clinic

TMJ Clinic

Reduce  your weight

A treatment 30 times more effective then IVIg

  Complete  guide on alternatives treatment of autoimmune disease please read our e-book 
 

 

A potent treatment for autoimmune diseases


 
An old therapy for a variety of autoimmune diseases is to be made more efficient thanks to 10 years of research. The original treatment, intravenous immunoglobulin (IVIG), is an amalgam of specific antibodies made from the pooled blood plasma of thousands of healthy donors. It has been used on- and off-label in patients with lupus, arthritis, asthma and other immune disorders to varying degrees of success. New research conducted by Rockefeller University (NY, USA) shows that understanding how the therapy works at the molecular level can help create a new version that is much more potent.

 

Jeffrey Ravetch, Head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology at Rockefeller, has been studying the paradox of IVIG: immunoglobulin (Ig)G antibodies, which trigger autoimmune diseases, are what give IVIG its anti-inflammatory properties when pooled from healthy donors. After pinning down the molecular mechanism at the source of the contradiction a single sugar molecule located at the very tip of some IgG antibodies Ravetch and his collaborators produced an engineered IgG molecule that was 30 times more effective than IVIG alone when given to arthritic mice. "This paper provides a clear route for developing an alternative for IVIG, which could be of great benefit to patients with autoimmune diseases," says Ravetch.  IVIg is also called IGIV as the  pharma industry uses the term IGIV or Immune globulin Intra Venous.

The technology has been licensed to Centaurus Pharmaceuticals (MA, USA), which is working to develop a product that can be used in clinical trials. Ravetch is confident that the resulting drug could potentially provide relief for a variety of patients, especially for those where IVIG has little effect. In lupus, the current preparation has such low activity that the amount required to effect a noticeable difference exceeds the amount that can be realistically derived from the blood supply. However, according to Ravetch: "With the recombinant form you can make an unlimited, potent supply."

 

Centaurus is among several developers of antibody drugs in New England that have grabbed interest from big drug makers and venture funds. Monoclonal antibodies, cloned from antibodies that attack pathogens, are the fastest growing class of drugs on the global market, with $20 billion in annual sales and yearly revenue increases of 14 percent projected until 2012, according to Datamonitor PLC, a London pharmaceutical market research firm


Locations of visitors to this page

 
 

 highest vitamin e

 Beet Root  anti cancer

research in autoimmune diseases

 Quran page